LGALS3 and Myocardial fibrosis: Elevated gal-3 concentrations have been linked to adverse cardiac outcomes and poorer prognosis, supporting its proposed role in cardiovascular risk stratification, assessment of myocardial fibrosis, and monitoring therapeutic response [5].